Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
Acurx Pharmaceuticals received FDA conditional acceptance and USPTO trademark allowance for the brand name CIFBEZY for its lead antibiotic candidate ibezapolstat. These branding milestones support the company's preparation for an international Phase 3 registration program targeting the acute treatment and recurrence reduction of C. difficile infection.
Key figures
- Drug Name
- ibezapolstat (CIFBEZY)
- Phase Of Trial
- Phase 3
- Annual us deaths
- 30000
- Annual us infections
- 500000
- Annual public health cost usd
- 5000000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.